Knocking on GDF15’s door for the treatment of type 2 diabetes mellitus - INRAE - Institut national de recherche pour l’agriculture, l’alimentation et l’environnement Accéder directement au contenu
Article Dans Une Revue Trends in Endocrinology and Metabolism = Trends in Endocrinology & Metabolism Année : 2022

Knocking on GDF15’s door for the treatment of type 2 diabetes mellitus

Résumé

Although a large number of drugs are available for the treatment of type 2 diabetes mellitus (T2DM), many patients do not achieve adequate disease control despite adhering to medication. Recent findings indicate that the pharmacological modulation of the stress-induced cytokine growth differentiation factor 15 (GDF15) shows promise for the treatment of T2DM. GDF15 suppresses appetite and reduces inflammation, increases thermogenesis and lipid catabolism, sustains AMP-activated protein kinase (AMPK) activity, and ameliorates insulin resistance and hepatic steatosis. In addition, circulating GDF15 levels are elevated in response to several antidiabetic drugs, including metformin, with GDF15 mediating some of their effects. Here, we review the mechanistic insights into the beneficial effects of recently explored therapeutic approaches that target GDF15 for the treatment of T2DM.
Fichier non déposé

Dates et versions

hal-03799299 , version 1 (05-10-2022)

Identifiants

Citer

David Aguilar-Recarte, Emma Barroso, Xavier Palomer, Walter Wahli, Manuel Vázquez-Carrera. Knocking on GDF15’s door for the treatment of type 2 diabetes mellitus. Trends in Endocrinology and Metabolism = Trends in Endocrinology & Metabolism , 2022, 33 (11), pp.741-754. ⟨10.1016/j.tem.2022.08.004⟩. ⟨hal-03799299⟩
14 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More